|
|
Post by n8 on Sept 6, 2017 8:21:56 GMT -5
|
|
|
|
Post by otherottawaguy on Sept 6, 2017 21:28:48 GMT -5
Got to love the Lantus ad that pops up to the right of the article...
|
|
|
|
Post by dreamboatcruise on Sept 11, 2017 23:30:02 GMT -5
In case anyone else wants to avoid entering an email address to access the report... it mostly is simply stating all the facts and financial info we know backward and forward. Here is the little bit of stuff that is there take on it. They don't make recommendation on buy or sell.
Stock Influences
Developments related to the investigational studies of treprostinil;
Improved sales and adoption of Afrezza;
Collaboration partnerships for the company’s Technosphere platform and other intellectual property; and
M&A activity.
Risk Factors
The company has significant debt, including $10 million scheduled for October 31, 2017. Should the company fail to address its financing situation, it could default on its obligations;
The success of the company is heavily dependent on Afrezza, which will require substantial additional capital to commercialize;
The company may not be able to secure international regulatory approval and/or partnerships for Afrezza; and
The company may not be able to develop any other product candidates using its proprietary technology.
Summary
Afrezza has already received FDA approval, is being actively marketed, and has a large addressable market. While the termination of the Sanofi agreement was a setback for prescriptions and sales, MannKind has mobilized a dedicated salesforce to improve adoption. Furthermore, the company’s Technosphere platform could produce valuable licensing partnership opportunities.
The primary issue is cash, and the projected burn rate for the second half of 2017 is significant. MannKind must explore all strategic alternatives for its intellectual property to improve operating cash flow and fortify its balance sheet.
|
|
